

Chapter 132

The Porphyrrias

David R. Bickers & Jorge Frank

REFERENCES

1. Puy H, Gouya L, Deybach JC: Porphyrrias. *Lancet* **375**:924, 2010
2. Whatley SD et al: Diagnostic strategies for autosomal dominant acute porphyrias: Retrospective analysis of 467 unrelated patients referred for mutational analysis of the *HMBS*, *CPOX*, or *PPOX* gene. *Clin Chem* **55**:1, 2009
3. Sassa S, Kappas A: Molecular aspects of the inherited porphyrias. *J Intern Med* **247**:169, 2000
4. Frank J, Christiano AM: The genetic bases of the porphyrias. *Skin Pharmacol Appl Skin Physiol* **11**:297, 1998
5. Whatley SD et al: C-terminal deletions in the *ALAS2* gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. *Am J Hum Genet* **83**:408, 2008
6. Puy H et al: Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria. *Am J Hum Genet* **60**:1373, 1997
7. Ratnaike S, Blake D: The diagnosis and follow-up of porphyria. *Pathology* **27**:142, 1995
8. Thunell S: Porphyrins, porphyrin metabolism and porphyrias. I. Update. *Scand J Clin Lab Invest* **60**:509, 2000
9. Riddle RD, Yamamoto M, Engel JD: Expression of delta-aminolevulinic synthase in avian cells: Separate genes encode erythroid-specific and nonspecific isozymes. *Proc Natl Acad Sci U S A* **86**:792, 1989
10. Yamamoto M et al: An immunochemical study of delta-aminolevulinic synthase and delta-aminolevulinic dehydratase in liver and erythroid cells of rat. *Arch Biochem Biophys* **245**:76, 1986
11. Thunell S, Pomp E, Brun A: Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. *Br J Clin Pharmacol* **64**:668, 2007
12. Crimlisk HL: The little imitator—porphyria: A neuropsychiatric disorder. *J Neurol Neurosurg Psychiatry* **62**:319, 1997
13. Moore MR, Hift RJ: Drugs in the acute porphyrias— toxicogenetic diseases. *Cell Mol Biol (Noisy-le-grand)* **43**:89, 1997
14. Schmidt GA, Corbridge TC: Appendicitis masquerading as acute porphyria. *Crit Care Med* **19**:443, 1991
15. Schuster HP: Abdominal pain in metabolic disorders. Guidelines for patient management for the general surgeon. *Zentralbl Chir* **113**:945, 1988
16. Brezis M et al: Hematin and propranolol in acute intermittent porphyria. Full recovery from quadriplegic coma and respiratory failure. *Eur Neurol* **18**:289, 1979
17. McEneaney D et al: Porphyric neuropathy—A rare and often neglected differential diagnosis of Guillain-Barre syndrome. *J Neurol Sci* **114**:231, 1993
18. Armas R et al: The hepatic porphyrias: Experience with 105 cases. *Rev Med Chil* **120**:259, 1992
19. Groenewald JZ et al: Linkage disequilibrium analysis in a recently founded population: Evaluation of the variegate porphyria founder in South African Afrikaners. *Am J Hum Genet* **62**:1254, 1998
20. Wolff C, Piderit F, Armas-Merino R: Deficiency of porphobilinogen synthase associated with acute crisis. Diagnosis of the first two cases in Chile by laboratory methods. *Eur J Clin Chem Clin Biochem* **29**:313, 1991
21. Sweeney GD: Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. *Clin Biochem* **19**:3, 1986
22. Poh-Fitzpatrick MB: The “priming phenomenon” in the acute phototoxicity of erythropoietic protoporphyria. *J Am Acad Dermatol* **21**:311, 1989
23. Lamola AA et al: Erythropoietic protoporphyria and lead intoxication: The molecular basis for difference in cutaneous photosensitivity. II. Different binding of erythrocyte protoporphyrin to hemoglobin. *J Clin Invest* **56**:1528, 1975
24. Piomelli S et al: Erythropoietic protoporphyria and lead intoxication: The molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro. *J Clin Invest* **56**:1519, 1975
25. Kauppinen R: Porphyrrias. *Lancet* **365**:241, 2005

26. Bodaness RS, Chan PC: Singlet oxygen as a mediator in the hematoporphyrin-catalyzed photooxidation of NADPH to NADP⁺ in deuterium oxide. *J Biol Chem* **252**:8554, 1977
27. Bickers DR, Dixit R, Mukhtar H: Hematoporphyrin photosensitization of epidermal microsomes results in destruction of cytochrome P-450 and in decreased monooxygenase activities and heme content. *Biochem Biophys Res Commun* **108**:1032, 1982
28. Kessel D, Rossi E: Determinants of porphyrin-induced photo-oxidation characterized by fluorescence and absorption spectra. *Photochem Photobiol* **35**:37, 1982
29. Blum HF: *Photodynamic Action and Diseases Caused by Light*. Princeton, Reinhold, 1941
30. Emiliani C, Delmelle M: The lipid solubility of porphyrins modulates their phototoxicity in membrane models. *Photochem Photobiol* **37**:487, 1983
31. He D, Soter NA, Lim HW: The late phase of hematoporphyrin derivative-induced phototoxicity in mice: Release of histamine and histologic changes. *Photochem Photobiol* **50**:91, 1989
32. Lim HW et al: Delayed phase of hematoporphyrin-induced phototoxicity: Modulation by complement, leukocytes, and antihistamines. *J Invest Dermatol* **84**:114, 1985
33. Schnait FG, Wolff K, Konrad K: Erythropoietic protoporphyria—Submicroscopic events during the acute photosensitivity flare. *Br J Dermatol* **92**:545, 1975
34. Yen A, Gigli I, Barrett KE: Dual effects of protoporphyrin and long wave ultraviolet light on histamine release from rat peritoneal and cutaneous mast cells. *J Immunol* **144**:4327, 1990
35. Sandberg S et al: Porphyrin-induced photodamage to isolated human neutrophils. *Photochem Photobiol* **34**:471, 1981
36. Baart De La Faille H: Experimental protoporphyria in hairless mice. In: *Photodermatitis*, edited by D Willoughby, J Girouds. Baltimore, University Park Press, 1980, p. 603
37. Varigos G, Schiltz JR, Bickers DR: Uroporphyrin I stimulation of collagen biosynthesis in human skin fibroblasts. A unique dark effect of porphyrin. *J Clin Invest* **69**:129, 1982
38. Latham PS, Bloomer JR: Protoporphyrin-induced photodamage: Studies using cultured skin fibroblasts. *Photochem Photobiol* **37**:553, 1983
39. Wakulchik SD, Schiltz JR, Bickers DR: Photolysis of protoporphyrin-treated human fibroblasts in vitro: Studies on the mechanism. *J Lab Clin Med* **96**:158, 1980
40. Herrmann G et al: Photosensitization of uroporphyrin augments the ultraviolet A-induced synthesis of matrix metalloproteinases in human dermal fibroblasts. *J Invest Dermatol* **107**:398, 1996
41. Lim HW, Gigli I: Role of complement in porphyrin-induced photosensitivity. *J Invest Dermatol* **76**:4, 1981
42. Lim HW et al: Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda. *N Engl J Med* **304**:212, 1981
43. Lim HW, Poh-Fitzpatrick MB, Gigli I: Activation of the complement system in patients with porphyrias after irradiation in vivo. *J Clin Invest* **74**:1961, 1984
44. Vasil KE, Magro CM: Cutaneous vascular deposition of C5b-9 and its role as a diagnostic adjunct in the setting of diabetes mellitus and porphyria cutanea tarda. *J Am Acad Dermatol* **56**:96, 2008
45. Pawliuk R et al: Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase. *J Invest Dermatol* **124**:256, 2005
46. Smith AG, Elder GH: Complex gene-chemical interactions: Hepatic uroporphyrin as a paradigm. *Chem Res Toxicol* **23**:712, 2010
47. Sarkany RP: The management of porphyria cutanea tarda. *Clin Exp Dermatol* **26**:225, 2001
48. Brunsting LA: Observations on porphyria cutanea tarda. *Arch Dermatol Syphilol* **70**:551, 1954
49. Brunsting LA, Mason, HL: Porphyria with cutaneous manifestations. *Arch Dermatol Syphilol* **60**:66, 1949
50. Grossman ME et al: Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. *Am J Med* **67**:277, 1979
51. Elder GH, Roberts AG: Uroporphyrinogen decarboxylase. *J Bioenerg Biomembr* **27**:207, 1995
52. Elder GH, Lee GB, Tovey JA: Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. *N Engl J Med* **299**:274, 1978
53. Benedetto AV, Kushner JP, Taylor JS: Porphyria cutanea tarda in three generations of a single family. *N Engl J Med* **298**:358, 1978

54. Held JL et al: Erythrocyte uroporphyrinogen decarboxylase activity in porphyria cutanea tarda: A study of 40 consecutive patients. *J Invest Dermatol* **93**:332, 1989
55. Kushner JP, Barbuto AJ, Lee GR: An inherited enzymatic defect in porphyria cutanea tarda: Decreased uroporphyrinogen decarboxylase activity. *J Clin Invest* **58**:1089, 1976
56. Jalil S et al: Associations among behavior-related susceptibility factors in porphyria cutanea tarda. *Clin Gastroenterol Hepatol* **8**:297, 2010
57. Brady et al: Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. *J Invest Dermatol* **115**:868, 2000
58. Phillips JD et al: Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase. *Blood* **98**:3179, 2001
59. The Human Gene Mutation Database (HGMD): <http://www.hgmd.cf.ac.uk/ac/index.php>
60. Roberts AG et al: Heterogeneity of familial porphyria cutanea tarda. *J Med Genet* **25**:669, 1988
61. Day RS, Eales L, Meissner D: Coexistent variegate porphyria and porphyria cutanea tarda. *N Engl J Med* **307**:36, 1982
62. Sieg I, Bhutani LK, Doss MO: Dual porphyria of coexisting variegata and cutanea tarda. *Eur J Clin Chem Clin Biochem* **33**:405, 1995
63. Watson CJ et al: Porphyria variegata and porphyria cutanea tarda in siblings: Chemical and genetic aspects. *Proc Natl Acad Sci U S A* **72**:5126, 1975
64. Doss MO: New form of dual porphyria: Coexistent acute intermittent porphyria and porphyria cutanea tarda. *Eur J Clin Invest* **19**:20, 1989
65. Shanley BC, Zail SS, Joubert SM: Effect of ethanol on liver delta-aminolaevulinic synthetase activity and urinary porphyrin excretion in symptomatic porphyria. *Br J Haematol* **17**:389, 1969
66. McColl KE et al: Abnormal haem biosynthesis in chronic alcoholics. *Eur J Clin Invest* **11**:461, 1981
67. Hourihane DO, Weir DG: Suppression of erythropoiesis by alcohol. *Br Med J* **1**:86, 1970
68. Kodama T et al: Changes in aminolevulinic synthase and aminolevulinic dehydratase activity in cirrhotic liver. *Gastroenterology* **84**:236, 1983
69. Levere RD: Stilbesterol-induced porphyria: Increased in hepatic delta-aminolevulinic acid synthetase. *Blood* **28**:569, 1966
70. Ochner R, Schmid R: Acquired porphyria in man and rat due to hexachlorobenzene intoxication. *Nature* **189**:499, 1961
71. Cripps DJ, Gocmen A, Peters HA: Porphyria turcica. Twenty years after hexachlorobenzene intoxication. *Arch Dermatol* **116**:46, 1980
72. Courtney KD: Hexachlorobenzene (HCB): A review. *Environ Res* **20**:225, 1979
73. Elder GH, Evans JO, Matlin SA: The effect of the porphyrogenic compound, hexachlorobenzene, on the activity of hepatic uroporphyrinogen decarboxylase in the rat. *Clin Sci Mol Med* **51**:71, 1976
74. Sinclair PR et al: Chlorinated biphenyls induce cytochrome P450IA2 and uroporphyrin accumulation in cultures of mouse hepatocytes. *Arch Biochem Biophys* **281**:225, 1990
75. Elder GH, Sheppard DM: Immunoreactive uroporphyrinogen decarboxylase is unchanged in porphyria caused by TCDD and hexachlorobenzene. *Biochem Biophys Res Commun* **109**:113, 1982
76. Poland A, Glover E: 2,3,7,8-Tetrachlorodibenzo-p-dioxin: A potent inducer of -aminolevulinic acid synthetase. *Science* **179**:476, 1973
77. Smith AG et al: Protection of the Cyp1a2(-/-) null mouse against uroporphyrin and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicol Appl Pharmacol* **173**:89, 2001
78. Schwetz BA et al: Toxicology of chlorinated dibenzo-p-dioxins. *Environ Health Perspect* **5**:87, 1973
79. Sweeny GD et al: Iron deficiency prevents liver toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Science* **204**:332, 1979
80. Jones KG, Sweeney GD: Dependence of the porphyrogenic effect of 2,3,7,8-tetrachlorodibenzo(p) dioxin upon inheritance of aryl hydrocarbon hydroxylase responsiveness. *Toxicol Appl Pharmacol* **53**:42, 1980
81. Kushner JP, Steinmuller DP, Lee GR: The role of iron in the pathogenesis of porphyria cutanea tarda. II. Inhibition of uroporphyrinogen decarboxylase. *J Clin Invest* **56**:661, 1975
82. Ajioka JD et al: Down-regulation of hepcidin in porphyria cutanea tarda. *Blood* **112**:4723, 2008
83. Lundvall O: The effect of the replenishment of iron stores after phlebotomy therapy in porphyria cutanea tarda. *Acta Med Scand* **189**:51, 1971
84. de Verneuil H, Sassa S, Kappas A: Purification and properties of uroporphyrinogen decarboxylase from human erythrocytes. A single enzyme catalyzing the four sequential decarboxylations of uroporphyrinogens I and III. *J Biol Chem* **258**:2454, 1983

85. Feldman ES, Bacon BR: Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene-induced porphyria with dietary carbonyl iron overload. *Hepatology* **9**:686, 1989
86. Roberts AG et al: Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. *Lancet* **349**:321, 1997
87. Roberts AG et al: The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. *Hepatology* **25**:159, 1997
88. Sampietro M et al: High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. *Hepatology* **27**:181, 1998
89. Bonkovsky HL: Mechanism of iron potentiation of hepatic uroporphyrin: Studies in cultured chick embryo liver cells. *Hepatology* **10**:354, 1989
90. Jones KG, Cole FM, Sweeney GD: The role of iron in the toxicity of 2,3,7,8-tetrachlorodibenzo-(p)-dioxin (TCDD). *Toxicol Appl Pharmacol* **61**:74, 1981
91. Kushner JP, Lee GR, Nacht S: The role of iron in the pathogenesis of porphyria cutanea tarda. An in vitro model. *J Clin Invest* **51**:3044, 1972
92. Phillips JD et al: A mouse model of familial porphyria cutanea tarda. *Proc Natl Acad Sci U S A* **98**:259, 2001
93. Chuang TY, Brashear R, Lewis C: Porphyria cutanea tarda and hepatitis C virus: A case-control study and meta-analysis of the literature. *J Am Acad Dermatol* **41**:31, 1999
94. Lim HW et al: Early-stage HIV infection and hepatitis C virus infection are associated with elevated serum porphyrin levels. *J Am Acad Dermatol* **39**:956, 1998
95. Cam C, Nigogosyan G: Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. *JAMA* **183**:88, 1963
96. Clemmensen O, Thomsen, K: Porphyria cutanea tarda and systemic lupus erythematosus. *Arch Dermatol* **118**:160, 1982
97. Solis JA et al: Association of porphyria cutanea tarda and primary liver cancer: Report of ten cases. *J Dermatol* **9**:131, 1982
98. Poh-Fitzpatrick MB et al: Porphyria cutanea tarda in two patients treated with hemodialysis for chronic renal failure. *N Engl J Med* **299**:292, 1978
99. Elder GH: Porphyrin metabolism in porphyria cutanea tarda. *Semin Hematol* **14**:227, 1977
100. Elder GH, Smith SG, Smyth SJ: Laboratory investigation of the porphyrias. *Ann Clin Biochem* **27**(Pt 5):395, 1990
101. Logan GM et al: Bile porphyrin analysis in the evaluation of variegate porphyria. *N Engl J Med* **324**:1408, 1991
102. Wolff K et al: Microscopic and fine structural aspects of porphyrias. *Acta Derm Venereol Suppl (Stockh)* **100**:17, 1982
103. Epstein JH, Tuffanelli DL, Epstein WL: Cutaneous changes in the porphyrias. A microscopic study. *Arch Dermatol* **107**:689, 1973
104. Ippen H: Allgemeinsymptome der späten Hautporphyrie (Porphyria cutanea tarda) als Hinweis für deren Behandlung. *Dtsch Med Wochenschr* **86**:127, 1961
105. Lundvall O: Phlebotomy treatment of porphyria cutanea tarda. *Acta Derm Venereol Suppl (Stockh)* **100**:107, 1982
106. Kordac V, Papezova R, Semradova M: Chloroquine in the treatment of porphyria cutanea tarda. *N Engl J Med* **296**:949, 1977
107. Vogler WR, Galambos JT, Olansky S: Biochemical effects of chloroquine therapy in porphyria cutanea tarda. *Am J Med* **49**:316, 1970
108. Swanbeck G, Wennersten G: Treatment of porphyria cutanea tarda with chloroquine and phlebotomy. *Br J Dermatol* **97**:77, 1977
109. Praga M et al: Treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine. *N Engl J Med* **316**:547, 1987
110. Rocchi E et al: Iron removal therapy in porphyria cutanea tarda: Phlebotomy versus slow subcutaneous desferrioxamine infusion. *Br J Dermatol* **114**:621, 1986
111. Stathers GM: Porphyrin-binding effect of cholestyramine. Results of in-vitro and in-vivo studies. *Lancet* **2**:780, 1966
112. Ramsay CA et al: The treatment of porphyria cutanea tarda by venesection. *Q J Med* **43**:1, 1974
113. Mukerji SK, Pimstone NR: Free radical mechanism of oxidation of uroporphyrinogen in the presence of ferrous iron. *Arch Biochem Biophys* **281**:177, 1990
114. Cappellini MD, Pattoneri P: Oral iron chelators. *Annu Rev Med* **60**:25, 2009
115. Saltzer EI, Redeker AG, Wilson JW: Porphyria cutanea tarda. Remission following chloroquine administration without adverse effects. *Arch Dermatol* **98**:496, 1968

116. Taljaard JJ et al: Studies on low dose chloroquine therapy and the action of chloroquine in symptomatic porphyria. *Br J Dermatol* 87:261, 1972
117. Malina L, Chlumsky J: A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. *Acta Derm Venereol* 61:346, 1981
118. Malkinson FD, Levitt L: Hydroxychloroquine treatment of porphyria cutanea tarda. *Arch Dermatol* 116:1147, 1980
119. Scholnick PL, Epstein J, Marver HS: The molecular basis of the action of chloroquine in porphyria cutanea tarda. *J Invest Dermatol* 61:226, 1973
120. Mustajoki P et al: Heme in the treatment of porphyrias and hematological disorders. *Semin Hematol* 26:1, 1989
121. Shieh S, Cohen JL, Lim HW: Management of porphyria cutanea tarda in the setting of chronic renal failure: A case report and review. *J Am Acad Dermatol* 42:645, 2000
122. Toback AC et al: Hepatoerythropoietic porphyria: Clinical, biochemical, and enzymatic studies in a three-generation family lineage. *N Engl J Med* 316:645, 1987
123. Burry JN, Lawrence JR: Phototoxic blisters from high frusemide dosage. *Br J Dermatol* 94:495, 1976
124. Ramsay CA, Obreshkova E: Photosensitivity from nalidixic acid. *Br J Dermatol* 91:523, 1974
125. Epstein JH, Seibert JS: Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization. *Arch Dermatol* 112:661, 1976
126. Girschich HJ et al: Naproxen-induced pseudoporphyria: Appearance of new skin lesions after discontinuation of treatment. *Scand J Rheumatol* 24:108, 1995
127. Baer RL: Cutaneous skin changes probably due to pyridoxine abuse. *J Am Acad Dermatol* 10:527, 1984
128. Riordan CA, Anstey A, Wojnarowska F: Isotretinoin-associated pseudoporphyria. *Clin Exp Dermatol* 18:69, 1993
129. Lecha M, Puy H, Deybach JC: Erythropoietic Protoporphyria. *Orphanet J Rare Dis* 4:19, 2009
130. Wahlin S et al: Erythropoietic protoporphyria in Sweden: Demographic, clinical, biochemical and genetic characteristics. *J Intern Med* 269:278, 2011
131. Bloomer JR: Characterization of deficient heme synthase activity in protoporphyria with cultured skin fibroblasts. *J Clin Invest* 65:321, 1980
132. Goerz G et al: Ferrochelatase activities in patients with erythropoietic protoporphyria and their families. *Br J Dermatol* 134:880, 1996
133. Sassa S et al: Studies in porphyria: Functional evidence for a partial deficiency of ferrochelatase activity in mitogen-stimulated lymphocytes from patients with erythropoietic protoporphyria. *J Clin Invest* 69:809, 1982
134. Taketani S, Fujita H: The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria. *J Bioenerg Biomembr* 27:231, 1995
135. Whatley SD et al: Molecular epidemiology of erythropoietic protoporphyria in the U.K. *Br J Dermatol* 162:642, 2010
136. Gouya L et al: The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. *Nat Genet* 30:27, 2002
137. Romslo I, Gadeholt HG, Hovding G: Erythropoietic protoporphyria terminating in liver failure. *Arch Dermatol* 118:668, 1982
138. Muley SA et al: Neuropathy in erythropoietic protoporphyrias. *Neurology* 51:262, 1998
139. Troadec MB: Targeted deletion of the mouse Mitoferrin1 gene: from anemia to protoporphyria. *Blood* 117:5494, 2011
140. Avner DL, Lee RG, Berenson MM: Protoporphyrin-induced cholestasis in the isolated in situ perfused rat liver. *J Clin Invest* 67:385, 1981
141. Sarkany RP, Alexander GJ, Cox TM: Recessive inheritance of erythropoietic protoporphyria with liver failure. *Lancet* 344:958, 1994
142. Schneider-Yin X et al: Recessive inheritance of erythropoietic protoporphyria with liver failure. *Lancet* 344:337, 1994
143. Cripps DJ, Scheuer PJ: Hepatobiliary changes in erythropoietic protoporphyria. *Arch Pathol* 80:500, 1965
144. Lamon JM, Poh-Fitzpatrick MB, Lamola AA: Hepatic protoporphyrin production in human protoporphyria. Effects of intravenous hematin and analysis of erythrocyte protoporphyrin distribution. *Gastroenterology* 79:115, 1980
145. Scholnick P, Marver HS, Schmid R: Erythropoietic protoporphyria: Evidence for multiple sites of excess protoporphyrin formation. *J Clin Invest* 50:203, 1971
146. Doss MO, Frank M: Hepatobiliary implications and complications in protoporphyria a 20-year study. *Clin Biochem* 22:223, 1989

147. Poh-Fitzpatrick MB et al: Rapid quantitative assay for erythrocyte porphyrins. *Arch Dermatol* **110**:225, 1974
148. Poh-Fitzpatrick MB, Lamola AA: Direct spectrofluorometry of diluted erythrocytes and plasma: A rapid diagnostic method in primary and secondary porphyriemias. *J Lab Clin Med* **87**:362, 1976
149. Peterka ES, Fusaro RM, Goltz RW: Erythropoietic protoporphyria. II. Histological and histochemical studies of cutaneous lesions. *Arch Dermatol* **92**:357, 1965
150. Cripps DJ et al: Four cases of erythropoietic protoporphyria presenting as light-sensitive lipoid proteinosis. *Proc R Soc Med* **57**:1095, 1964
151. Ryan EA, Madill GT: Electron microscopy of the skin in erythropoietic protoporphyria. *Br J Dermatol* **80**:561, 1968
152. Breathnach SM et al: Immunohistochemical studies of amyloid P component and fibronectin in erythropoietic protoporphyria. *Br J Dermatol* **108**:267, 1983
153. Klatskin G, Bloomer JR: Birefringence of hepatic pigment deposits in erythropoietic protoporphyria. Specificity of polarization microscopy in the identification of hepatic protoporphyrin deposits. *Gastroenterology* **67**:294, 1974
154. Wolff K: Liver inclusions in erythropoietic protoporphyria. *Eur J Clin Invest* **5**:21, 1975
155. Mathews-Roth MM et al: Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. *Arch Dermatol* **113**:1229, 1977
156. Minder EI et al: A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. *Cell Mol Biol (Noisy-le-grand)* **55**:84, 2009
157. Corbett MF et al: The long-term treatment with beta-carotene in erythropoietic protoporphyria: A controlled trial. *Br J Dermatol* **97**:655, 1977
158. Wertz K et al: Beta-carotene inhibits UVA-induced matrix metalloprotease 1 and 10 expression in keratinocytes by a singlet oxygen-dependent mechanism. *Free Radic Biol Med* **37**:654, 2004
159. Wertz K et al: beta-Carotene interferes with ultraviolet light A-induced gene expression by multiple pathways. *J Invest Dermatol* **124**:428, 2005
160. Mathews-Roth MM et al: A double-blind study of cysteine photoprotection in erythropoietic protoporphyria. *Photodermatol Photoimmunol Photomed* **10**:244, 1994
161. Bechtel MA, Bertolone SJ, Hodge SJ: Transfusion therapy in a patient with erythropoietic protoporphyria. *Arch Dermatol* **117**:99, 1981
162. McCullough AJ et al: Fecal protoporphyrin excretion in erythropoietic protoporphyria: Effect of cholestyramine and bile acid feeding. *Gastroenterology* **94**:177, 1988
163. Gordeuk VR et al: Iron therapy for hepatic dysfunction in erythropoietic protoporphyria. *Ann Intern Med* **105**:27, 1986
164. Milligan A et al: Erythropoietic protoporphyria exacerbated by oral iron therapy. *Br J Dermatol* **119**:63, 1988
165. Seth AK et al: Liver transplantation for porphyria: Who, when and how? *Liver Transpl* **13**:1219, 2007
166. Wahlin S et al: Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. *J Hepatol* **46**:174, 2007
167. Rand EB et al: Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. *Pediatrics* **118**:1896, 2006
168. Pawliuk R et al: Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. *Nat Med* **5**:768, 1999
169. Cernik C, Haller N, Mostow EN: Adult-onset erythropoietic porphyria in the setting of MDS. *Arch Dermatol* **145**:948, 2009
170. Tsai SF, Bishop DF, Desnick RJ: Purification and properties of uroporphyrinogen III synthase from human erythrocytes. *J Biol Chem* **262**:1268, 1987
171. Tsai SF, Bishop DF, Desnick RJ: Human uroporphyrinogen III synthase: Molecular cloning, nucleotide sequence, and expression of a full-length cDNA. *Proc Natl Acad Sci U S A* **85**:7049, 1988
172. Phillips JD et al: Congenital erythropoietic porphyria due to a mutation in *GATA-1*: The first *trans*-acting mutation causative for a human porphyria. *Blood* **109**:2618, 2007
173. Fritsch C et al: Congenital erythropoietic porphyria. *J Am Acad Dermatol* **36**:594, 1997
174. Poh-Fitzpatrick MB: Erythropoietic porphyrias: Current mechanistic, diagnostic, and therapeutic considerations. *Semin Hematol* **14**:211, 1977
175. Nordmann Y et al: Coexistent hereditary coproporphyria and congenital erythropoietic porphyria (Gunther disease). *J Inherit Metab Dis* **13**:687, 1990
176. Piomelli S et al: Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. *N Engl J Med* **314**:1029, 1986

177. Pimstone NR, Gandhi SN, Mukerji SK: Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria. *N Engl J Med* **316**:390, 1987
178. Minder EI, Schneider-Yin X, Moll F: Lack of effect of oral charcoal in congenital erythropoietic porphyria. *N Engl J Med* **330**:1092, 1994
179. Shaw PH et al: Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: A case report and review of the literature. *Bone Marrow Transplant* **27**:101, 2001
180. Thomas C et al: Correction of congenital erythropoietic porphyria by bone marrow transplantation. *J Pediatr* **129**:453, 1996
181. Waldenström J: Studien Über Porphyrie. *Acta Med Scand* **92** (Suppl. 82):1, 1937
182. Anderson PM, Desnick RJ: Purification and properties of uroporphyrinogen I synthase from human erythrocytes. Identification of stable enzyme-substrate intermediates. *J Biol Chem* **255**:1993, 1980
183. Chretien S et al: Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. *Proc Natl Acad Sci U S A* **85**:6, 1988
184. Grandchamp B: Acute intermittent porphyria. *Semin Liver Dis* **18**:17, 1998
185. de Matteis F: Disturbances of liver porphyrin metabolism caused by drugs. *Pharmacol Rev* **19**:523, 1967
186. McColl KE, Moore R: The porphyrias: An example of pharmacogenetic disease. *Scott Med J* **26**:32, 1981
187. McDougall AJ, McLeod JG: Autonomic neuropathy, II: Specific peripheral neuropathies. *J Neurol Sci* **138**:1, 1996
188. Hoesch K: Über die Auswertung der Urobilinogenurie und die "umgekehrte" Urobilinogenurie. *Dtsch Med Wochenschr* **72**:704, 1947
189. Thunell S et al: Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. *Scand J Clin Lab Invest* **60**:541, 2000
190. Elder GH, Hift RJ: Treatment of acute porphyria. *Hosp Med* **62**:422, 2001
191. Mustajoki P, Nordmann Y: Early administration of heme arginate for acute porphyric attacks. *Arch Intern Med* **153**:2004, 1993
192. Anderson KE et al: A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. *Arch Intern Med* **150**:1469, 1990
193. Handschin Cet al: Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. *Cell* **122**:505, 2005
194. Dhar GJ et al: Effects of hematin in hepatic porphyria. Further studies. *Ann Intern Med* **83**:20, 1975
195. Goetsch CA, Bissell DM: Instability of hematin used in the treatment of acute hepatic porphyria. *N Engl J Med* **315**:235, 1986
196. Tenhunen R, Mustajoki P: Acute porphyria: Treatment with heme. *Semin Liver Dis* **18**:53, 1998
197. de Rooij F et al: Six new protoporphyrinogen oxidase mutations in Dutch variegate porphyria patients and the R59W mutation in historical perspective (abstract). *Acta Haematol* **98**:96, 1997
198. Meissner PN et al: A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. *Nat Genet* **13**:95, 1996
199. Mustajoki P: Variegate porphyria. *Ann Intern Med* **89**:238, 1978
200. Deybach JC et al: Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. *Hum Mol Genet* **5**:407, 1996
201. Frank J et al: Homozygous variegate porphyria: Missense mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. *J Invest Dermatol* **108**:647, 1997
202. Lam H et al: Molecular basis of variegate porphyria: A de novo insertion mutation in the protoporphyrinogen oxidase gene. *Hum Genet* **99**:126, 1997
203. Taketani S et al: The human protoporphyrinogen oxidase gene (PPOX): Organization and location to chromosome 1. *Genomics* **29**:698, 1995
204. Frank J et al: Identification of a founder mutation in the protoporphyrinogen oxidase gene in variegate porphyria patients from Chile. *Hum Hered* **51**:160, 2001
205. Dean G: *The Porphyrins*. Philadelphia, Lippincott, 1963
206. Hift RJ et al: Homozygous variegate porphyria: An evolving clinical syndrome. *Postgrad Med J* **69**:781, 1993
207. Palmer RA et al: Homozygous variegate porphyria: A compound heterozygote with novel mutations in the protoporphyrinogen oxidase gene. *Br J Dermatol* **144**:866, 2001
208. Rimington C, Lockwood WH, Belcher RV: The excretion of porphyrin-peptide conjugates in porphyria variegate. *Clin Sci* **35**:211, 1968

209. Kushner JP: Laboratory diagnosis of the porphyrias. *N Engl J Med* **324**:1432, 1991
210. Eales L, Dowdle EB: The place of screening tests and quantitative investigations in the diagnosis of the porphyrias, with particular reference to variegate and symptomatic porphyria. *S Afr J Lab Clin Med* **40**:63, 1966
211. Poh-Fitzpatrick MB: A plasma porphyrin fluorescence marker for variegate porphyria. *Arch Dermatol* **116**:543, 1980
212. Cramers M, Jepsen LV: Porphyria variegata: Failure of chloroquin treatment. *Acta Derm Venereol* **60**:89, 1980
213. Lamoril J et al: A molecular defect in coproporphyrinogen oxidase gene causing harderoporphyria, a variant form of hereditary coproporphyrin. *Hum Mol Genet* **4**:275, 1995
214. Lee DS et al: Structural basis of hereditary coproporphyrin. *Proc Natl Acad Sci U S A* **102**:14232, 2005
215. Schmitt C et al: Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyrin or erythropoietic harderoporphyria. *Hum Mol Genet* **14**:3089, 2005
216. Fujita H et al: Characterization and expression of cDNA encoding coproporphyrinogen oxidase from a patient with hereditary coproporphyrin. *Hum Mol Genet* **3**:1807, 1994
217. Sassa S et al: Molecular defects of the coproporphyrinogen oxidase gene in hereditary coproporphyrin. *Cell Mol Biol (Noisy-le-grand)* **43**:59, 1997
218. Grandchamp B, Lamoril J, Puy H: Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyrin. *J Bioenerg Biomembr* **27**:215, 1995
219. Moder KG, Schwenk NM: A coproporphyrin-like syndrome induced by glipizide. *Mayo Clin Proc* **66**:312, 1991
220. Doss M et al: New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. *Klin Wochenschr* **57**:1123, 1979
221. Gross U et al: 5-Aminolevulinic acid dehydratase deficiency porphyria: A twenty-year clinical and biochemical follow-up. *Clin Chem* **44**:1892, 1998
222. Sassa S: ALAD porphyria. *Semin Liver Dis* **18**:95, 1998
223. Thunell S, Holmberg L, Lundgren J: Aminolaevulinic acid dehydratase porphyria in infancy. A clinical and biochemical study. *J Clin Chem Clin Biochem* **25**:5, 1987
224. Ben-Ezzer J, Oelsner H, Szeinberg A: Genetic polymorphism of delta-aminolevulinic acid dehydratase in several population groups in Israel. *Hum Hered* **37**:229, 1987
225. Harraway JR et al: Dual porphyria with mutations in both the UROD and HMBS genes. *Ann Clin Biochem* **43**:80, 2006
226. Akagi R et al: Dual gene defects involving delta-aminolaevulinic acid dehydratase and coproporphyrinogen oxidase in a porphyria patient. *Br J Haematol* **132**:237, 2006
227. Lim HW et al: Photosensitivity, abnormal porphyrin profile, and sideroblastic anemia. *J Am Acad Dermatol* **27**:287, 1992
228. Rothstein G, Lee R, Cartwright GE: Sideroblastic anemia with dermal photosensitivity and greatly increased erythrocyte protoporphyrin. *N Engl J Med* **280**:587, 1969
229. Sato Y et al: [A case of sideroblastic anemia with dermal photosensitivity and increased erythrocyte protoporphyrin (author's transl)]. *Rinsho Ketsueki* **22**:1971, 1981
230. Fontanellas A et al: Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. *Gene Ther* **8**:618, 2001
231. de Verneuil H, Moreau-Gaudry F, Ged C: [A model of congenital erythropoietic porphyria for gene transfer in hematopoietic cells]. *Transfus Clin Biol* **4**:263, 1997